Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

A Machine Learning Platform to Optimize the Translation of Personalized Network Models to the Clinic.

Salvucci M, Rahman A, Resler AJ, Udupi GM, McNamara DA, Kay EW, Laurent-Puig P, Longley DB, Johnston PG, Lawler M, Wilson R, Salto-Tellez M, Van Schaeybroeck S, Rafferty M, Gallagher WM, Rehm M, Prehn JHM.

JCO Clin Cancer Inform. 2019 Apr;3:1-17. doi: 10.1200/CCI.18.00056.

2.

USP17 is required for trafficking and oncogenic signaling of mutant EGFR in NSCLC cells.

McCann AP, Smyth P, Cogo F, McDaid WJ, Jiang L, Lin J, Evergren E, Burden RE, Van Schaeybroeck S, Scott CJ, Burrows JF.

Cell Commun Signal. 2018 Nov 8;16(1):77. doi: 10.1186/s12964-018-0291-5.

3.

Transcriptional subtyping and CD8 immunohistochemistry identifies poor prognosis stage II/III colorectal cancer patients who benefit from adjuvant chemotherapy.

Allen WL, Dunne PD, McDade S, Scanlon E, Loughrey M, Coleman H, McCann C, McLaughlin K, Nemeth Z, Syed N, Jithesh P, Arthur K, Wilson R, Coyle V, McArt D, Murray GI, Samuel L, Nuciforo P, Jimenez J, Argiles G, Dienstmann R, Tabernero J, Messerini L, Nobili S, Mini E, Sheahan K, Ryan E, Johnston PG, Van Schaeybroeck S, Lawler M, Longley DB.

JCO Precis Oncol. 2018 Jun 13;2018. doi: 10.1200/PO.17.00241.

4.

The Unfolded Protein Response: A Novel Therapeutic Target for Poor Prognostic BRAF Mutant Colorectal Cancer.

Forsythe N, Refaat A, Javadi A, Khawaja H, Weir JA, Emam H, Allen WL, Burkamp F, Popovici V, Jithesh PV, Isella C, Labonte MJ, Mills IG, Johnston PG, Van Schaeybroeck S.

Mol Cancer Ther. 2018 Jun;17(6):1280-1290. doi: 10.1158/1535-7163.MCT-17-0603. Epub 2018 Feb 26.

5.

Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges.

Bradley CA, Salto-Tellez M, Laurent-Puig P, Bardelli A, Rolfo C, Tabernero J, Khawaja HA, Lawler M, Johnston PG, Van Schaeybroeck S; MErCuRIC consortium.

Nat Rev Clin Oncol. 2018 Jan 23;15(3):150. doi: 10.1038/nrclinonc.2018.13. [Epub ahead of print]

PMID:
29358775
6.

Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges.

Bradley CA, Salto-Tellez M, Laurent-Puig P, Bardelli A, Rolfo C, Tabernero J, Khawaja HA, Lawler M, Johnston PG, Van Schaeybroeck S; MErCuRIC consortium.

Nat Rev Clin Oncol. 2017 Sep;14(9):562-576. doi: 10.1038/nrclinonc.2017.40. Epub 2017 Apr 4. Review. Erratum in: Nat Rev Clin Oncol. 2018 Jan 23;:.

PMID:
28374784
7.

Deubiquitylating enzymes in receptor endocytosis and trafficking.

McCann AP, Scott CJ, Van Schaeybroeck S, Burrows JF.

Biochem J. 2016 Dec 15;473(24):4507-4525. Review.

PMID:
27941029
8.

Transcriptional upregulation of c-MET is associated with invasion and tumor budding in colorectal cancer.

Bradley CA, Dunne PD, Bingham V, McQuaid S, Khawaja H, Craig S, James J, Moore WL, McArt DG, Lawler M, Dasgupta S, Johnston PG, Van Schaeybroeck S.

Oncotarget. 2016 Nov 29;7(48):78932-78945. doi: 10.18632/oncotarget.12933.

9.

BCL-2 system analysis identifies high-risk colorectal cancer patients.

Lindner AU, Salvucci M, Morgan C, Monsefi N, Resler AJ, Cremona M, Curry S, Toomey S, O'Byrne R, Bacon O, Stühler M, Flanagan L, Wilson R, Johnston PG, Salto-Tellez M, Camilleri-Broët S, McNamara DA, Kay EW, Hennessy BT, Laurent-Puig P, Van Schaeybroeck S, Prehn JHM.

Gut. 2017 Dec;66(12):2141-2148. doi: 10.1136/gutjnl-2016-312287. Epub 2016 Sep 23.

PMID:
27663504
10.

A Stepwise Integrated Approach to Personalized Risk Predictions in Stage III Colorectal Cancer.

Salvucci M, Würstle ML, Morgan C, Curry S, Cremona M, Lindner AU, Bacon O, Resler AJ, Murphy ÁC, O'Byrne R, Flanagan L, Dasgupta S, Rice N, Pilati C, Zink E, Schöller LM, Toomey S, Lawler M, Johnston PG, Wilson R, Camilleri-Broët S, Salto-Tellez M, McNamara DA, Kay EW, Laurent-Puig P, Van Schaeybroeck S, Hennessy BT, Longley DB, Rehm M, Prehn JH.

Clin Cancer Res. 2017 Mar 1;23(5):1200-1212. doi: 10.1158/1078-0432.CCR-16-1084. Epub 2016 Sep 20.

11.

Immune-Derived PD-L1 Gene Expression Defines a Subgroup of Stage II/III Colorectal Cancer Patients with Favorable Prognosis Who May Be Harmed by Adjuvant Chemotherapy.

Dunne PD, McArt DG, O'Reilly PG, Coleman HG, Allen WL, Loughrey M, Van Schaeybroeck S, McDade S, Salto-Tellez M, Longley DB, Lawler M, Johnston PG.

Cancer Immunol Res. 2016 Jul;4(7):582-91. doi: 10.1158/2326-6066.CIR-15-0302. Epub 2016 May 13.

12.

Challenging the Cancer Molecular Stratification Dogma: Intratumoral Heterogeneity Undermines Consensus Molecular Subtypes and Potential Diagnostic Value in Colorectal Cancer.

Dunne PD, McArt DG, Bradley CA, O'Reilly PG, Barrett HL, Cummins R, O'Grady T, Arthur K, Loughrey MB, Allen WL, McDade SS, Waugh DJ, Hamilton PW, Longley DB, Kay EW, Johnston PG, Lawler M, Salto-Tellez M, Van Schaeybroeck S.

Clin Cancer Res. 2016 Aug 15;22(16):4095-104. doi: 10.1158/1078-0432.CCR-16-0032. Epub 2016 May 5.

13.

Delivering a research-enabled multistakeholder partnership for enhanced patient care at a population level: The Northern Ireland Comprehensive Cancer Program.

Lawler M, Gavin A, Salto-Tellez M, Kennedy RD, Van Schaeybroeck S, Wilson RH, Harkin DP, Grayson M, Boyd RE, Hamilton PW, McArt DG, James J, Robson T, Ladner RD, Prise KM, O'Sullivan JM, Harrison T, Murray L, Johnston PG, Waugh DJ.

Cancer. 2016 Mar 1;122(5):664-73. doi: 10.1002/cncr.29814. Epub 2015 Dec 22. No abstract available.

14.

Overcoming Resistance to Targeted Therapies in Cancer.

Redmond KL, Papafili A, Lawler M, Van Schaeybroeck S.

Semin Oncol. 2015 Dec;42(6):896-908. doi: 10.1053/j.seminoncol.2015.09.028. Epub 2015 Sep 25. Review.

PMID:
26615134
15.

Connectivity mapping using a combined gene signature from multiple colorectal cancer datasets identified candidate drugs including existing chemotherapies.

Wen Q, O'Reilly P, Dunne PD, Lawler M, Van Schaeybroeck S, Salto-Tellez M, Hamilton P, Zhang SD.

BMC Syst Biol. 2015;9 Suppl 5:S4. doi: 10.1186/1752-0509-9-S5-S4. Epub 2015 Sep 1.

16.

Probing a 3,4'-bis-guanidinium diaryl derivative as an allosteric inhibitor of the Ras pathway.

Diez-Cecilia E, Carson R, Kelly B, van Schaeybroeck S, Murray JT, Rozas I.

Bioorg Med Chem Lett. 2015 Oct 1;25(19):4287-92. doi: 10.1016/j.bmcl.2015.07.082. Epub 2015 Aug 18.

PMID:
26318998
17.

EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer.

Dunne PD, Dasgupta S, Blayney JK, McArt DG, Redmond KL, Weir JA, Bradley CA, Sasazuki T, Shirasawa S, Wang T, Srivastava S, Ong CW, Arthur K, Salto-Tellez M, Wilson RH, Johnston PG, Van Schaeybroeck S.

Clin Cancer Res. 2016 Jan 1;22(1):230-242. doi: 10.1158/1078-0432.CCR-15-0603. Epub 2015 Aug 17.

18.

The prognostic value of the stem-like group in colorectal cancer using a panel of immunohistochemistry markers.

Ong CW, Chong PY, McArt DG, Chan JY, Tan HT, Kumar AP, Chung MC, Clément MV, Soong R, Van Schaeybroeck S, Waugh DJ, Johnston PG, Dunne PD, Salto-Tellez M.

Oncotarget. 2015 May 20;6(14):12763-73.

19.

HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF-Mutant Colorectal Cancer by Downregulation of c-FLIPL.

Carson R, Celtikci B, Fenning C, Javadi A, Crawford N, Carbonell LP, Lawler M, Longley DB, Johnston PG, Van Schaeybroeck S.

Clin Cancer Res. 2015 Jul 15;21(14):3230-3240. doi: 10.1158/1078-0432.CCR-14-2701. Epub 2015 Mar 26.

20.

USP17 is required for clathrin mediated endocytosis of epidermal growth factor receptor.

Jaworski J, de la Vega M, Fletcher SJ, McFarlane C, Greene MK, Smyth AW, Van Schaeybroeck S, Johnston JA, Scott CJ, Rappoport JZ, Burrows JF.

Oncotarget. 2014 Aug 30;5(16):6964-75.

21.

ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancer.

Van Schaeybroeck S, Kalimutho M, Dunne PD, Carson R, Allen W, Jithesh PV, Redmond KL, Sasazuki T, Shirasawa S, Blayney J, Michieli P, Fenning C, Lenz HJ, Lawler M, Longley DB, Johnston PG.

Cell Rep. 2014 Jun 26;7(6):1940-55. doi: 10.1016/j.celrep.2014.05.032. Epub 2014 Jun 12.

22.

Differential affinity of FLIP and procaspase 8 for FADD's DED binding surfaces regulates DISC assembly.

Majkut J, Sgobba M, Holohan C, Crawford N, Logan AE, Kerr E, Higgins CA, Redmond KL, Riley JS, Stasik I, Fennell DA, Van Schaeybroeck S, Haider S, Johnston PG, Haigh D, Longley DB.

Nat Commun. 2014 Feb 28;5:3350. doi: 10.1038/ncomms4350.

23.

Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer.

Turkington RC, Longley DB, Allen WL, Stevenson L, McLaughlin K, Dunne PD, Blayney JK, Salto-Tellez M, Van Schaeybroeck S, Johnston PG.

Cell Death Dis. 2014 Feb 6;5:e1046. doi: 10.1038/cddis.2014.10.

24.

Prognostic and therapeutic relevance of FLIP and procaspase-8 overexpression in non-small cell lung cancer.

Riley JS, Hutchinson R, McArt DG, Crawford N, Holohan C, Paul I, Van Schaeybroeck S, Salto-Tellez M, Johnston PG, Fennell DA, Gately K, O'Byrne K, Cummins R, Kay E, Hamilton P, Stasik I, Longley DB.

Cell Death Dis. 2013 Dec 5;4:e951. doi: 10.1038/cddis.2013.481.

25.

AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer.

Dunne PD, McArt DG, Blayney JK, Kalimutho M, Greer S, Wang T, Srivastava S, Ong CW, Arthur K, Loughrey M, Redmond K, Longley DB, Salto-Tellez M, Johnston PG, Van Schaeybroeck S.

Clin Cancer Res. 2014 Jan 1;20(1):164-75. doi: 10.1158/1078-0432.CCR-13-1354. Epub 2013 Oct 29.

26.

Cancer drug resistance: an evolving paradigm.

Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG.

Nat Rev Cancer. 2013 Oct;13(10):714-26. doi: 10.1038/nrc3599. Review.

PMID:
24060863
27.

Connectivity Mapping for Candidate Therapeutics Identification Using Next Generation Sequencing RNA-Seq Data.

McArt DG, Dunne PD, Blayney JK, Salto-Tellez M, Van Schaeybroeck S, Hamilton PW, Zhang SD.

PLoS One. 2013 Jun 26;8(6):e66902. doi: 10.1371/journal.pone.0066902. Print 2013.

28.

Identification of galanin and its receptor GalR1 as novel determinants of resistance to chemotherapy and potential biomarkers in colorectal cancer.

Stevenson L, Allen WL, Turkington R, Jithesh PV, Proutski I, Stewart G, Lenz HJ, Van Schaeybroeck S, Longley DB, Johnston PG.

Clin Cancer Res. 2012 Oct 1;18(19):5412-26. doi: 10.1158/1078-0432.CCR-12-1780. Epub 2012 Aug 2.

29.

Pharmacogenomic profiling and pathway analyses identify MAPK-dependent migration as an acute response to SN38 in p53 null and p53-mutant colorectal cancer cells.

Allen WL, Turkington RC, Stevenson L, Carson G, Coyle VM, Hector S, Dunne P, Van Schaeybroeck S, Longley DB, Johnston PG.

Mol Cancer Ther. 2012 Aug;11(8):1724-34. doi: 10.1158/1535-7163.MCT-12-0207. Epub 2012 Jun 4.

30.

Identification of an acetylation-dependant Ku70/FLIP complex that regulates FLIP expression and HDAC inhibitor-induced apoptosis.

Kerr E, Holohan C, McLaughlin KM, Majkut J, Dolan S, Redmond K, Riley J, McLaughlin K, Stasik I, Crudden M, Van Schaeybroeck S, Fenning C, O'Connor R, Kiely P, Sgobba M, Haigh D, Johnston PG, Longley DB.

Cell Death Differ. 2012 Aug;19(8):1317-27. doi: 10.1038/cdd.2012.8. Epub 2012 Feb 10.

31.

A systems biology approach identifies SART1 as a novel determinant of both 5-fluorouracil and SN38 drug resistance in colorectal cancer.

Allen WL, Stevenson L, Coyle VM, Jithesh PV, Proutski I, Carson G, Gordon MA, Lenz HJ, Van Schaeybroeck S, Longley DB, Johnston PG.

Mol Cancer Ther. 2012 Jan;11(1):119-31. doi: 10.1158/1535-7163.MCT-11-0510. Epub 2011 Oct 25.

32.

Implementing prognostic and predictive biomarkers in CRC clinical trials.

Van Schaeybroeck S, Allen WL, Turkington RC, Johnston PG.

Nat Rev Clin Oncol. 2011 Feb 15;8(4):222-32. doi: 10.1038/nrclinonc.2011.15. Review.

PMID:
21321566
33.

Oncogenic Kras promotes chemotherapy-induced growth factor shedding via ADAM17.

Van Schaeybroeck S, Kyula JN, Fenton A, Fenning CS, Sasazuki T, Shirasawa S, Longley DB, Johnston PG.

Cancer Res. 2011 Feb 1;71(3):1071-80. doi: 10.1158/0008-5472.CAN-10-0714. Epub 2010 Dec 10.

34.

Chemotherapy-induced activation of ADAM-17: a novel mechanism of drug resistance in colorectal cancer.

Kyula JN, Van Schaeybroeck S, Doherty J, Fenning CS, Longley DB, Johnston PG.

Clin Cancer Res. 2010 Jul 1;16(13):3378-89. doi: 10.1158/1078-0432.CCR-10-0014. Epub 2010 Jun 22.

35.

Prognostic significance of TRAIL signaling molecules in stage II and III colorectal cancer.

McLornan DP, Barrett HL, Cummins R, McDermott U, McDowell C, Conlon SJ, Coyle VM, Van Schaeybroeck S, Wilson R, Kay EW, Longley DB, Johnston PG.

Clin Cancer Res. 2010 Jul 1;16(13):3442-51. doi: 10.1158/1078-0432.CCR-10-0052. Epub 2010 Jun 22.

36.

Src and ADAM-17-mediated shedding of transforming growth factor-alpha is a mechanism of acute resistance to TRAIL.

Van Schaeybroeck S, Kelly DM, Kyula J, Stokesberry S, Fennell DA, Johnston PG, Longley DB.

Cancer Res. 2008 Oct 15;68(20):8312-21. doi: 10.1158/0008-5472.CAN-07-6736.

37.

Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells.

Van Schaeybroeck S, Kyula J, Kelly DM, Karaiskou-McCaul A, Stokesberry SA, Van Cutsem E, Longley DB, Johnston PG.

Mol Cancer Ther. 2006 May;5(5):1154-65.

38.

Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy.

Van Schaeybroeck S, Karaiskou-McCaul A, Kelly D, Longley D, Galligan L, Van Cutsem E, Johnston P.

Clin Cancer Res. 2005 Oct 15;11(20):7480-9.

39.

Ileal perforation caused by cytomegalovirus infection in an immunocompetent adult.

Van Schaeybroeck S, Hiele M, Miserez M, Croes R.

Acta Clin Belg. 2002 Jun-Jul;57(3):154-7.

PMID:
12212357
40.

Ectopic ACTH-syndrome due to a thymic carcinoid tumor.

Van Schaeybroeck S, Van Imschoot S, Cochez P.

Acta Clin Belg. 2002 Jan-Feb;57(1):23-5.

PMID:
12017752

Supplemental Content

Loading ...
Support Center